Search results for:
Ondine Biomedical Leverages Mela Solutions’ 90% NHS ICU Footprint to Advance Commercial Evaluation and Quantify Steriwave® Financial Impact
Strategic data collaboration taps into national critical care software infrastructure across ~4,500 NHS beds to assess rapid hospital ROI, capacity utilisation, and infection reduction. Ondine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial therapies to prevent hospital infections, today announces a strategic data and evaluation collaboration [...]
Steriwave ICU Study Outcomes Presented at CSRT2026
SMURF Feasibility Study of Nasal Photodisinfection Presented at National Respiratory Conference Ondine Biomedical Inc. ("Ondine"), a leader in light-activated antimicrobial therapies to prevent and treat hospital infections, announces that results from the SMURF feasibility pilot study ("Suppression of Microbial Burden to Reduce Pneumonia in Critical Illness") were presented at the [...]
Steriwave ICU Study Shows 39.5% Pneumonia Drop
Pioneering research from Royal Columbian Hospital Foundation shows a significant decrease in pneumonia rates and establishes a new benchmark for ICU infection prevention. Ondine Biomedical Inc. (AIM: OBI) is pleased to announce that Royal Columbian Hospital Foundation (“RCHF”)’s Advancing Innovation in Medicine (“AIM”) Research Team, at one of Canada’s leading [...]
For Media Information
5654 & Company
